Author: KAZIA THERAPEUTICS LIMITED.

Posted Date:

January 30, 2026

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

KAZIA THERAPEUTICS LIMITED.

January 30, 2026
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

KAZIA THERAPEUTICS LIMITED.

January 28, 2026